P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 249.35 INR 0.2%
Market Cap: 330.6B INR
Have any thoughts about
Piramal Pharma Ltd?
Write Note

Piramal Pharma Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Piramal Pharma Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Short-Term Debt
â‚ą11.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Debt
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Short-Term Debt
â‚ą1.5B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Piramal Pharma Ltd
Glance View

Market Cap
329.1B INR
Industry
Pharmaceuticals

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.

PPLPHARMA Intrinsic Value
139.65 INR
Overvaluation 44%
Intrinsic Value
Price
P

See Also

What is Piramal Pharma Ltd's Short-Term Debt?
Short-Term Debt
11.7B INR

Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Short-Term Debt amounts to 11.7B INR.

What is Piramal Pharma Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 1Y
-10%

Over the last year, the Short-Term Debt growth was -10%.

Back to Top